These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

432 related items for PubMed ID: 24511610

  • 1. Photosensitive Pt(IV)-azide prodrug-loaded nanoparticles exhibit controlled drug release and enhanced efficacy in vivo.
    Xiao H, Noble GT, Stefanick JF, Qi R, Kiziltepe T, Jing X, Bilgicer B.
    J Control Release; 2014 Jan 10; 173():11-7. PubMed ID: 24511610
    [Abstract] [Full Text] [Related]

  • 2. Novel Pt(IV) prodrug self-assembled nanoparticles with enhanced blood circulation stability and improved antitumor capacity of oxaliplatin for cancer therapy.
    Fu Y, Kong Y, Li X, Cheng D, Hou Y, Li Y, Li T, Xiao Y, Zhang Q, Rong R.
    Drug Deliv; 2023 Dec 10; 30(1):2171158. PubMed ID: 36744299
    [Abstract] [Full Text] [Related]

  • 3. Functional fluorescent nonporous silica nanoparticles as carriers for Pt(IV) anticancer prodrugs.
    Ravera M, Perin E, Gabano E, Zanellato I, Panzarasa G, Sparnacci K, Laus M, Osella D.
    J Inorg Biochem; 2015 Oct 10; 151():132-42. PubMed ID: 26277416
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. An Iron Oxide Nanocarrier Loaded with a Pt(IV) Prodrug and Immunostimulatory dsRNA for Combining Complementary Cancer Killing Effects.
    Hernández-Gil J, Cobaleda-Siles M, Zabaleta A, Salassa L, Calvo J, Mareque-Rivas JC.
    Adv Healthc Mater; 2015 May 10; 4(7):1034-42. PubMed ID: 25846677
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. A core cross-linked polymeric micellar platium(IV) prodrug with enhanced anticancer efficiency.
    Hou J, Shang J, Jiao C, Jiang P, Xiao H, Luo L, Liu T.
    Macromol Biosci; 2013 Jul 10; 13(7):954-65. PubMed ID: 23744619
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Functionalized nonporous silica nanoparticles as carriers for Pt(iv) anticancer prodrugs.
    Ravera M, Gabano E, Zanellato I, Perin E, Arrais A, Osella D.
    Dalton Trans; 2016 Nov 01; 45(43):17233-17240. PubMed ID: 27722707
    [Abstract] [Full Text] [Related]

  • 10. Engineering liposomal nanoparticles of cholesterol-tethered amphiphilic Pt(iv) prodrugs with prolonged circulation time in blood.
    Datta P, Bang S, Yue Z, Beach T, Stilgenbauer M, Wang H, Bowers DJ, Kurokawa M, Xiao H, Zheng YR.
    Dalton Trans; 2020 Jun 23; 49(24):8107-8113. PubMed ID: 32490446
    [Abstract] [Full Text] [Related]

  • 11. Platinum(iv) anticancer prodrugs - hypotheses and facts.
    Gibson D.
    Dalton Trans; 2016 Aug 16; 45(33):12983-91. PubMed ID: 27214873
    [Abstract] [Full Text] [Related]

  • 12. Photoactivatable platinum complexes.
    Bednarski PJ, Mackay FS, Sadler PJ.
    Anticancer Agents Med Chem; 2007 Jan 16; 7(1):75-93. PubMed ID: 17266506
    [Abstract] [Full Text] [Related]

  • 13. Human Serum Albumin Conjugated Nanoparticles for pH and Redox-Responsive Delivery of a Prodrug of Cisplatin.
    Shi H, Cheng Q, Yuan S, Ding X, Liu Y.
    Chemistry; 2015 Nov 09; 21(46):16547-54. PubMed ID: 26405808
    [Abstract] [Full Text] [Related]

  • 14. Targeted iron nanoparticles with platinum-(IV) prodrugs and anti-EZH2 siRNA show great synergy in combating drug resistance in vitro and in vivo.
    Yu C, Ding B, Zhang X, Deng X, Deng K, Cheng Z, Xing B, Jin D, Ma P, Lin J.
    Biomaterials; 2018 Feb 09; 155():112-123. PubMed ID: 29175080
    [Abstract] [Full Text] [Related]

  • 15. Efficient co-delivery of a Pt(IV) prodrug and a p53 activator to enhance the anticancer activity of cisplatin.
    Ma R, Wang Y, Yan L, Ma L, Wang Z, Chan HC, Chiu SK, Chen X, Zhu G.
    Chem Commun (Camb); 2015 May 07; 51(37):7859-62. PubMed ID: 25854514
    [Abstract] [Full Text] [Related]

  • 16. Multipronged Design of Light-Triggered Nanoparticles To Overcome Cisplatin Resistance for Efficient Ablation of Resistant Tumor.
    Li Y, Deng Y, Tian X, Ke H, Guo M, Zhu A, Yang T, Guo Z, Ge Z, Yang X, Chen H.
    ACS Nano; 2015 Oct 27; 9(10):9626-37. PubMed ID: 26365698
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Nucleus-targeting Oxaplatin(IV) prodrug Amphiphile for enhanced chemotherapy and immunotherapy.
    Wei D, Yan J, Cao Z, Han S, Sun Y.
    J Control Release; 2024 Sep 27; 373():216-223. PubMed ID: 39002797
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.